1 — A randomized controlled trial published in the Journal of the American Nutrition Association (Korovljev et al., 2025) explored the effects of creatine supplementation taken daily for 8 weeks in a group of perimenopausal and menopausal women. Researchers reported a 16.4% increase in frontal brain creatine levels vs. 0.9% in the placebo group, significant improvements in reaction time, and a favorable trend in mood swing reduction over the study period.
2 — Peer-reviewed research published in Nutrients (Smith-Ryan et al., 2021) confirmed that women have 70–80% lower endogenous creatine stores than men and that estrogen directly regulates creatine metabolism — meaning this gap accelerates as estrogen declines during perimenopause and menopause.
3 — Longitudinal studies confirm perimenopausal women experience up to 10% total muscle mass loss in the first five years after menopause, with associated declines in metabolic rate and insulin sensitivity (PMC, 2025).
Results may vary. Please consult your physician before beginning any supplement program.
THIS IS AN ADVERTORIAL AND NOT AN ACTUAL NEWS ARTICLE, BLOG, OR CONSUMER PROTECTION UPDATE
© 2026 LumiLitt. All rights reserved.
This is an advertisement for the LumiLitt Creatine Boost System™ and is intended for informational purposes only. The clinical studies referenced were not conducted using LumiLitt products specifically; formulation and results may differ. All information provided by LumiLitt does not constitute medical advice and should not be used as a replacement for professional medical guidance. Please consult your healthcare provider regarding any change in treatment or supplementation.
The views and opinions expressed are solely those of LumiLitt or a testimonial from a verified LumiLitt customer based on her real-life experiences. Individual results may vary.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.